Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers

This study has investigated a panel of immunomarkers in non‐small cell lung carcinoma (NSCLC). Unsupervised hierarchical clustering analysis was used to investigate the possibility of identifying different subgroups in NSCLC based on their molecular expression profile rather than morphological features. A tissue microarray consisting of 284 cases of NSCLC was constructed. Immunohistochemistry was used to detect the presence of 18 biomarkers including synaptophysin, chromogranin, bombesin, NSE, GFI1, ASH‐1, p53, p63, p21, p27, E2F‐1, cyclin D1, Bcl‐2, TTF‐1, CEA, HER2/neu, cytokeratin 5/6, and pancytokeratin. Univariate analysis of all 18 markers for prognostic significance was performed. Immunohistochemical scoring data for NSCLC were analysed by unsupervised hierarchical clustering analysis. Kaplan–Meier survival curves were plotted for the different cluster groups of lung tumours identified by this method. Analysis of the three different World Health Organization (WHO) subtypes (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) of NSCLC individually showed that different markers were significant in different subtypes. For example, p53 and p63 were significant for squamous cell carcinoma (p = 0.007 and p = 0.03, respectively), whereas cyclin D1 and HER2/neu were significant prognostic markers for adenocarcinoma (p = 0.025 and p = 0.015, respectively). These markers were not significant prognostic predictors for NSCLC as a group. Hierarchical clustering analysis of NSCLC produced four separate cluster groups, although the vast majority of cases were found in two cluster groups, one dominated by squamous cell carcinoma and the other by adenocarcinoma. The clinical outcomes of cases from the four cluster groups were not significantly different. Prognostic indicators vary between different morphological subtypes of NSCLC. Unsupervised hierarchical clustering analysis, based on an extended immunoprofile, identifies two main cluster groups corresponding to adenocarcinoma and squamous cell carcinoma; cases of large cell carcinomas are assigned to one of these two groups based on their molecular phenotype. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  M. Papotti,et al.  Chromogranin A gene expression in non‐small cell lung carcinomas , 1998, The Journal of pathology.

[2]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[3]  H. Wada,et al.  Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  A. Okamura,et al.  Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. , 2002, Lung cancer.

[5]  S. Steinberg,et al.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.

[6]  A. Churg.  The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. , 1978, Human pathology.

[7]  D. Lane,et al.  The relationship of p53 immunostaining to survival in carcinoma of the lung. , 1992, British Journal of Cancer.

[8]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.

[10]  M. Volm,et al.  Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype. , 2002, Anticancer research.

[11]  J. Kern,et al.  The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. , 1998, Lung cancer.

[12]  J. H. Lee,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1999.0661 , 2022 .

[13]  K. Chow,et al.  Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. , 1998, The Annals of thoracic surgery.

[14]  Matt van de Rijn,et al.  Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry , 2002, Modern Pathology.

[15]  A. Giordano,et al.  Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. , 1999, American journal of respiratory cell and molecular biology.

[16]  Mark A. Stephenson,et al.  The Expression of Cyclins D1 and E in Predicting Short-Term Survival in Squamous Cell Carcinoma of the Lung , 2000, Modern Pathology.

[17]  E. Brambilla,et al.  Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.

[18]  Michael Ruogu Zhang,et al.  Molecular characteristics of non-small cell lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Torri,et al.  HER‐2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma , 2002, Cancer.

[20]  K. Junker.  Prognostic factors in stage I/II non-small cell lung cancer. , 2001, Lung cancer.

[21]  J. Jassem,et al.  Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. , 2002, Lung cancer.

[22]  K. Nagashima,et al.  Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. , 2001, Lung cancer.

[23]  G. C. Nogueira,et al.  Stages I and II , 2000 .

[24]  R. Lloyd,et al.  Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. , 1985, Human pathology.

[25]  F. Hirsch,et al.  HER2/neu expression in malignant lung tumors. , 2002, Seminars in oncology.

[26]  M. Volm,et al.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.

[27]  T. Seidal,et al.  Interpretation and Quantification of Immunostains , 2001, The American journal of surgical pathology.

[28]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[29]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  C. Gilks,et al.  Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein , 1993, Molecular and cellular biology.

[32]  Y. Yatabe,et al.  Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[34]  M. You,et al.  Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. , 2002, Neoplasia.

[35]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[36]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[38]  平島 奈緒子.  Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas : A comparative immunohistochemical and fluorescence in situ hybridization study , 2001 .

[39]  S. Raab,et al.  Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. , 2002, The Annals of thoracic surgery.

[40]  H. Kato,et al.  Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer , 2003, International journal of cancer.

[41]  O. Stoeltzing,et al.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.

[42]  L. Mao.  Molecular abnormalities in lung carcinogenesis and their potential clinical implications. , 2001, Lung cancer.

[43]  K. Sugimachi,et al.  Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. , 2001, Oncology reports.

[44]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[45]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[46]  B. Westerman,et al.  Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  S. Raab,et al.  Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. , 2002, Human pathology.

[48]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Y. Fujiwara,et al.  Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection , 1994, Japanese journal of cancer research : Gann.

[50]  H. Zoghbi,et al.  The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival , 2003, Development.

[51]  Armando Santoro,et al.  Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  R. Salgia,et al.  Role of receptor tyrosine kinases in lung cancer. , 2003, Methods in molecular medicine.

[53]  S. Baylin,et al.  Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Koshikawa,et al.  Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[55]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  W. El-Deiry,et al.  Clinical implications of p53 mutations in lung cancer. , 2003, Methods in molecular medicine.